ENDO ANCHOR SYSTEM - HELI-FX AAA
Report
- Report Number
- 9612164-2025-02966
- Event Type
- Malfunction
- Date Received
- June 17, 2025
- Date of Event
- May 8, 2023
- Report Date
- July 4, 2025
- Manufacturer
- MEDTRONIC IRELAND
- Product Code
- OTD
- PMA / PMN Number
- K140036
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- AU
- Reporter Occupation
- PHYSICIAN
- Health Professional
- Yes
Narratives
MEDTRONIC RECEIVED THE FOLLOWING INFORMATION FROM A JOURNAL ARTICLE ENTITLED; ¿FENESTRATED ENDOVASCULAR AORTIC REPAIR AFTER FAILED E NDOVASCULAR AORTIC REPAIR¿ TAHER F, PLIMON M, WALTER C, WEISS G, KLIEWER M, ASSADIAN A, FALKENSAMMER J JOURNAL OF ENDOVASCULAR THERAPY 2025, VOL. 32(1) 233¿241 HTTPS://DOI.ORG/10.1177/15266028231174113 A2: AVERAGE AGE A3A: MAJORITY SEX MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.
B5; ADDITIONAL INFORMATION RECEIVED: PER THE AUTHOR , THE TERM ¿FAILED¿ EVAR IS NOT REFERRING TO DEVICE FAILURES OR ADVERSE EVENTS, BUT RATHER PROGRESSION OF AORTIC DISEASE WHICH LEAD TO FEVAR IN EVAR DUE TO INSUFFICIENT PROXIMAL LANDING ZONE. ANOTHER REASON FOR THIS (ESPECIALLY WHEN THIS OCCURS EARLY) IS WHEN EVAR IS DONE OUTSIDE OF IFU (WITH INSUFFICIENT PROXIMAL LANDING ZONE). IN THIS STUDY, THESE PROCEDURES USUALLY OCCURRED A RELATIVELY LONG TIME AFTER EVAR (IN THE CASE OF THE ENDURANT DEVICES IN OUR STUDY UP TO 10 YEARS AFTER THE ENDURANT EVAR). NOTEWORTHY, THIS STUDY FOUND THAT THE STEERABLE SHEATH PROVIDED BY MEDTRONIC (TOURGUIDE) MAY HAVE BEEN INVALUABLE IN PERFORMING THESE COMPLEX CASES (WITH A POSITIVE EFFECT ON SUCCESS OF AND, ANECDOTALLY, TIME REQUIRED FOR CANNULATION AND CONNECTION OF FENESTRATIONS). MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.
LITERATURE WAS REVIEWED REGARDING ¿FENESTRATED ENDOVASCULAR AORTIC REPAIR AFTER FAILED ENDOVASCULAR AORTIC REPAIR¿ THE TIME FRAME OF THIS STUDY WAS OVER A SEVEN YEAR PERIOD. THIS RETROSPECTIVE STUDY ASSESSED THE TECHNICAL OUTCOME OF FENESTRATED EN DOVASCULAR AORTIC REPAIR (FENESTRATED EVAR; FEVAR) AFTER PRIOR EVAR. 35 PATIENTS WERE INCLUDED WHO MET THE CRITERIA OF UNDERGOING A FEVAR AFTER FAILED EVAR. PRIMARY STENT GRAFTS USED IN THE EVAR PROCEDURE INCLUDED MDT ENDURANT, TALENT STENT GRAFT AS WELL AS NON-MDT STENT GRAFTS. THREE CASES ALSO HAD ENDOANCHORS IMPLANTED DURING THE INDEX PROCEDURE. TIME FROM EVAR IMPLANTATION TO FEVAR WAS 51.7±32.9 MONTHS. NON-MDT CUSTOM MADE STENT GRAFTS WERE IMPLANTED DURING THE FEVAR PROCEDURES. AMONG THE PATIENT POPULATION THE FOLLOWING MALFUNCTIONS OCCURRED (CONFIRMED AS AN INDICATION TO PERFORM THE FEVAR: IA ENDOLEAK NO FURTHER INFORMATION WAS PROVIDED PERTAINING TO MEDTRONIC PRODUCTS
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1594559 | ENDO ANCHOR SYSTEM - HELI-FX AAA | ENDOVASCULAR SUTURING SYSTEM | OTD | MEDTRONIC IRELAND | SA-85 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 73 YR | Male | Required Intervention |